API | tanespimycin

tanespimycin Report issue

Small molecule Experimental

AACT ChEMBL DrugBank MeSH PubChem

Active Ingredient History

NOW

Tanespimycin is a derivative of the antibiotic geldanamycin that is being studied in the treatment of cancer, specifically in younger patients with certain types of leukemia or solid tumors, especially kidney tumors. ^Wikipedia

Chemistry

SMILES: CO[C@H]1C[C@H](C)Cc2c(O)c(NC(=O)\C(=C\C=C/[C@H](OC)[C@@H](OC(=O)N)\C(=C\[C@H](C)[C@H]1O)\C)\C)cc(O)c2NCC=C
InChIKey: OAKGNIRUXAZDQF-TXHRRWQRSA-N
Mol. Mass: 587.71
ALogP: 4.16 Partition coefficient
ChEMBL Molecules:

retaspimycin

tanespimycin

retaspimycin hydrochloride

More Chemistry

Pharmacology

Mechanism of Action:
- Heat shock protein HSP 90-alpha (Homo sapiens) ^UniProt
- Heat shock protein HSP 90-beta (Homo sapiens) ^UniProt
Multi-specific: Missing data
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

17aag | 17-aag | 17 allylamino-17-demethoxygeldanamycin | 17-(allylamino)-17-demethoxygeldanamycin | 17-(allylamino)-17-demethoxy-geldanamycin | 17-allylamino-17-demethoxygeldanamycin | 17-allylamino-17-demethoxygeldanamycin hydroquinone | 17-allylamino-17-demethoxygeldanamycin hydroquinone salt | 17-allylaminogeldanamycin | 17-allyl-aminogeldanamycin | 17-allylamino-geldanamycin | ((4e,6e,8s,9s,10e,12s,13r,14s,16r)-13-hydroxy-8,14-dimethoxy-4,10,12,16-tetramethyl-3,20,22-trioxo-19-(prop-2-enylamino)-2-azabicyclo(16.3.1)docosa-4,6,10,18,21-pentaen-9-yl) carbamate | abi-010 | bms-722782 | cnf1010 | ipi493 | ipi 493 | ipi-493 | ipi504 | ipi 504 | ipi-504 | nsc 330507 | nsc-330507 | retaspimycin | retaspimycin hcl | retaspimycin hydrochloride | tanespimycin

Organizations (25)

Research & Development (25)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (63)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (63)

Acne Vulgaris (Phase 2)

Anemia, Refractory (Phase 1)

Breast Neoplasms (Phase 2)

Burkitt Lymphoma (Phase 1)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Chondrosarcoma (Phase 1)

Colorectal Neoplasms (Phase 1)

Gastrointestinal Stromal Tumors (Phase 3)

Hamartoma (Phase 2)

Head and Neck Neoplasms (Phase 1)

Hematologic Neoplasms (Phase 1)

Hodgkin Disease (Phase 2)

Intraocular Lymphoma (Phase 1)

Kidney Neoplasms (Phase 2)

Leiomyosarcoma (Phase 1)

Leukemia (Phase 2)

Leukemia, Eosinophilic, Acute (Phase 1)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 1)

Leukemia-Lymphoma, Adult T-Cell (Phase 1)

Leukemia, Monocytic, Acute (Phase 1)

Leukemia, Myeloid, Acute (Phase 1)

Leukemia, Myeloid, Chronic-Phase (Phase 1)

Leukemia, Myelomonocytic, Acute (Phase 1)

Leukemia, Myelomonocytic, Chronic (Phase 1)

Leukemia, Prolymphocytic (Phase 1)

Liposarcoma (Phase 2)

Lung Neoplasms (Phase 2)

Lymphoma (Phase 2)

Lymphoma, AIDS-Related (Phase 1)

Lymphoma, B-Cell, Marginal Zone (Phase 1)

Lymphoma, Follicular (Phase 1)

Lymphoma, Large B-Cell, Diffuse (Phase 1)

Lymphoma, Large-Cell, Anaplastic (Phase 2)

Lymphoma, Large-Cell, Immunoblastic (Phase 1)

Lymphoma, Mantle-Cell (Phase 2)

Lymphoma, Non-Hodgkin (Phase 1)

Lymphoma, Primary Cutaneous Anaplastic Large Cell (Phase 1)

Lymphoma, T-Cell (Phase 1)

Lymphomatoid Granulomatosis (Phase 1)

Melanoma (Phase 2)

Multiple Myeloma (Phase 3)

Myelodysplastic Syndromes (Phase 1)

Myeloproliferative Disorders (Phase 2)

Neoplasm Metastasis (Phase 1)

Neoplasms (Phase 1/Phase 2)

Neuroblastoma (Phase 1)

Osteosarcoma (Phase 1)

Ovarian Neoplasms (Phase 2)

Pancreatic Neoplasms (Phase 2)

Precancerous Conditions (Phase 2)

Precursor B-Cell Lymphoblastic Leukemia-Lymphoma (Phase 1)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 1)

Prostatic Neoplasms (Phase 2)

Rhabdomyosarcoma (Phase 1)

Sarcoma (Phase 1)

Sarcoma, Ewing (Phase 1)

Sezary Syndrome (Phase 1)

Stomach Neoplasms (Phase 1)

Thyroid Neoplasms (Phase 2)

Transplantation (Phase 1)

Urinary Bladder Neoplasms (Phase 1)

von Hippel-Lindau Disease (Phase 2)

Waldenstrom Macroglobulinemia (Phase 1)

Overview

Highest Phase: Phase 3
# of Trials: 51
# of Trial Organizations: 25

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue